Advancing drug development in gynecologic malignancies

Julia A. Beaver, Robert L. Coleman, Rebecca C. Arend, Deborah K. Armstrong, Sanjeeve Bala, Gordon B. Mills, Anil K. Sood, Thomas J. Herzog

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Gynecologic malignancies continue to be a major cause of morbidity and mortality in the United States despite recent advances in oncologic therapies. To realize the promise of immunotherapy and biomarker-driven approaches to improve clinical outcomes for patients, better communication among stakeholders in the drug development and approval pathways is needed. To this end, the FDA-AACR-SGO Drug Development in Gynecologic Malignancies Workshop brought together clinicians, patient advocates, researchers, industry representatives, and regulators in June 2018, to review the state of the science in gynecologic cancers and explore how scientific advances impact approval processes. Topics of discussion and key takeaways are summarized in this Perspectives in Regulatory Science and Policy article. Single-agent immunotherapies have demonstrated variable and often modest response rates among gynecologic cancers. Combination therapies and other novel approaches, such as cell-based therapies, may show improved efficacy compared with single-agent immunotherapies; however, utilizing innovative clinical trial designs will be necessary to progress further. Companion and complementary diagnostics inform physicians of potential benefits of specific therapeutics for patients; however, they serve different functions that have important regulatory implications, thus trialists should understand the distinctions between diagnostic types. PARP inhibitors hold great promise for treating ovarian cancers, both as monotherapies and in combination with chemotherapeutics, other targeted agents, and immunotherapies. Rare gynecologic cancers often exhibit unique molecular characteristics that can serve as effective targets to which novel therapeutics can be developed. This workshop highlighted the importance of future open discussions on scientific and regulatory challenges in drug development for gynecologic malignancies.

Original languageEnglish (US)
Pages (from-to)4874-4880
Number of pages7
JournalClinical Cancer Research
Issue number16
StatePublished - Aug 15 2019

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Advancing drug development in gynecologic malignancies'. Together they form a unique fingerprint.

Cite this